SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.